Indications for Osteochondral Allograft Transplantation

Sponsor
University of Missouri-Columbia (Other)
Overall Status
Recruiting
CT.gov ID
NCT03711747
Collaborator
(none)
10
1
45
0.2

Study Details

Study Description

Brief Summary

With IRB approval, a prospective single-cohort clinical trial will be performed to assess safety and efficacy of total biologic arthroplasty of the ankle. With informed consent, patients (n=10) who require tibio-talar arthroplasty based on physical examination and diagnostic imaging will be enrolled. Primary criteria for inclusion will be Grade IV changes in the articular cartilage of the tibial plafond and/or talar dome as determined by physical examination, diagnostic imaging and/or arthroscopy by the attending surgeon. Exclusion criteria include acute injury to any other part of the affected lower extremity or inability to comply with the protocol.

After enrollment, patients will undergo standard ankle radiography and complete assessments (described below). Size-matched (standard clinical methodology) MOPSTM allografts (Musculoskeletal Transplant Foundation, Edison, NJ) from the same donor will be obtained to treat the entire tibiotalar joint. The affected joint will be treated with OCA transplants using our current technique and instrumentation. Osteochondral grafts including MOPSTM OCAs are regulated under U.S. Food and Drug Administration (FDA) section 361 of the Public Health Service Act and 21 Code of Federal Regulation 1271 that defines human cells, tissues or cellular or tissue based products (HCT/P).

Patients will follow a managed post-operative rehabilitation protocol that is standard for those that have had an osteochondral allograft to their ankle.

Range of motion and patient-reported outcome measures (PROMs) including VAS pain score, AOFAS, and PROMIS Mobility as well as complete radiographs (XR) of the affected ankle will be obtained prior to surgery and at 6 weeks, 3 months, 6 months, and 12 months after surgery to evaluate healing, function and evidence for arthrosis. MRIs for cartilage composition (12 months after surgery, and serum and urine biomarkers for treatment monitoring (preop, 6 and 12 months after surgery) will be performed. We will document all adverse events and complications, including joint or incision infection, graft failure, hardware failure, and arthrofibrosis. Patients with a VAS pain score >5 beyond 3 months postoperatively or clinical or diagnostic imaging evidence for nonunion or graft collapse will undergo MRI of the ankle to determine the appropriate clinical course of action. OCA survival will be determined based on maintenance of acceptable levels of pain (<2 VAS) and function and/or need for revision surgery or total ankle arthroplasty, fusion, or amputation.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Osteochondral allograft ankle

Study Design

Study Type:
Observational
Anticipated Enrollment :
10 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Indications for Osteochondral Allograft Transplantation by Evaluating Safety and Efficacy of Total Biologic Total Joint Replacement of Ankle Post-traumatic Osteoarthritis (PTOA)
Actual Study Start Date :
Jan 1, 2019
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Oct 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Post-traumatic Ankle OA

Post-traumatic ankle OA and requiring osteochondral allograft to tibia and/or talus in ankle

Procedure: Osteochondral allograft ankle
Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus

Outcome Measures

Primary Outcome Measures

  1. Visual Analog Scale (VAS) score [12 Months]

    Pain assessment which measures what a patient rates their pain between 0 and 10, with 0 being no pain, and 10 being the most pain

Secondary Outcome Measures

  1. American Orthopaedic Foot and Ankle Society (AOFAS) score [12 Months]

    This measurement tool measures a patient's function out of 100, with 100 being highest amount of function

  2. PROMIS - Physical Function and Mobility [12 Months]

    A survey related to physical function and mobility

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Grade IV changes in the articular cartilage of the tibial plafond and/or talar dome as determined by physical exam, diagnostic imaging, and/or arthroscopy by the attending surgeon ii. Between the age of 18-55
Exclusion Criteria:
  1. Acute injury to any other part of the affected lower extremity ii. Inability to comply with protocol iii. BMI greater than 40 iv. The subject is either pregnant or a prisoner v. Currently involved in worker's compensation case at the time of enrollment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Missouri Orthopaedic Institute Columbia Missouri United States 65202

Sponsors and Collaborators

  • University of Missouri-Columbia

Investigators

  • Principal Investigator: James Stannard, MD, University of Missouri, Department of Orthopaedic Surgery

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
James Stannard, Professor, Orthopedic Surgery, University of Missouri-Columbia
ClinicalTrials.gov Identifier:
NCT03711747
Other Study ID Numbers:
  • 2011144
First Posted:
Oct 18, 2018
Last Update Posted:
Oct 21, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by James Stannard, Professor, Orthopedic Surgery, University of Missouri-Columbia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 21, 2021